S&P 500: Outlook Constructive but Concerns Remain
As the S&P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we...
304 Views
Venture Corp (VMS SP) And Other Singapore Tech Stocks: The Baby or the Bath Water? - Part 1
The recent trade spat between the US and China has brought pain to the Singapore Tech sector. Investors have indiscriminately dumped the sector...
254 Views
Human Longevity
At KIS capital we try to keep ourselves at the forefront of technology and innovation, attempting to identify which industries may blossom, and...
526 Views
WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China
WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares. Proceeds will be used...
784 Views
WuXi Biologics: Pass on This Valuation
The company's underwriters have announced a price range of HK$18.60 - HK$20.60 which implies a market cap of US$2.7-3.0 billion. We recommend...
759 Views